Aragen Life Sciences, a Contract Research Development and Manufacturing Organisation (CRDMO), will operationalise its state-of-the-art formulation manufacturing facility in the Mallapur campus, Hyderabad, India by January 2023.

Through its integrated drug material and drug product development and manufacture, the facility will improve the company’s capacity to deliver clinical supplies to clients.

With expansion plans already in place to add nano milling and hot melt extrusion capabilities, the new plant will offer a wide range of dosage form capabilities for oral solids, liquids, topicals, and films, as well as manufacturing technologies for granulation, film coating, spray drying, and tableting. These additional features will improve Aragen’s early-stage New Chemical Entity (NCE) development offerings further and give customers the convenience of discovering and developing medications from a single location.